Migräne (Topiramate)

• Topiramate is used in neurological conditions that involve abnormal neuronal excitability.
• Migraine prophylaxis: reduces the frequency and severity of migraine attacks in adults.
• Partial‑onset seizures (epilepsy): used as adjunctive therapy to control seizure episodes.
• Generalized tonic‑clonic seizures: added to existing regimens to improve seizure control.

• Topiramate acts by multiple mechanisms: it blocks voltage‑dependent sodium channels, enhances the inhibitory effect of gamma‑aminobutyric acid (GABA) at GABA‑A receptors, antagonizes excitatory glutamate signaling through AMPA/kainate receptors, and weakly inhibits carbonic anhydrase. These actions collectively reduce neuronal hyperexcitability and suppress the propagation of abnormal electrical activity in the brain.

Topiramate may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Paresthesia: tingling or numbness in the limbs.
• Altered taste: reduced ability to perceive sweet flavors.
• Weight loss: mild to moderate decrease in body weight.
• Fatigue: feeling of tiredness or low energy.

Serious or Rare Side Effects

• Metabolic acidosis: accumulation of acid in the blood.
• Kidney stones: formation of renal calculi due to altered urine pH.
• Acute angle‑closure glaucoma: sudden increase in intra‑ocular pressure.

• Before initiating therapy with Topiramate, several precautionary measures should be considered.
• Renal function: assess baseline kidney function and monitor periodically.
• Pregnancy: avoid use during pregnancy as it is classified as category D.
• History of glaucoma: evaluate intra‑ocular pressure and monitor for visual changes.
• Cognitive effects: watch for confusion, difficulty concentrating or memory problems.
• Concomitant carbonic anhydrase inhibitors: avoid due to increased risk of metabolic acidosis.
• Store at room temperature below 25°C: keep in the original container, protect from moisture.

Topiramate can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

• Valproic acid: may increase risk of hyperammonemia and hepatic toxicity.
• Carbonic anhydrase inhibitors (e.g., acetazolamide): additive risk of metabolic acidosis.
• CYP3A4 inducers (e.g., rifampin, carbamazepine): can markedly reduce topiramate plasma concentrations.

Moderate Interactions (Monitor Closely)

• Oral contraceptives: may reduce hormonal efficacy, requiring alternative contraception.
• CNS depressants (e.g., benzodiazepines, alcohol): enhanced sedative effects.
• Lithium: combined use may increase the likelihood of kidney stone formation.